author-photo

Brian L. Hodous

Amgen

35

Papers

975

Citations

Citation Trend

Filter By

Papers (28) Sort By

Journal Conference Others

Abstract A112: Drug discovery efforts on the RNA protein methyltransferase METTL3/METTL14

2019 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (1)
Targeting kinases with precision

2018 Molecular and Cellular Oncology
Show All
- Source
- Cite
- Save
Citations (5)
A precision therapy against cancers driven by KIT/PDGFRA mutations

2017 Science Translational Medicine
Show All
- Source
- Cite
- Save
Citations (91)
Abstract 791: BLU-285, the first selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (11)
Crystal Structure of FGFR4 with an Irreversible Inhibitor

2015
Show All
- Source
- Cite
- Save
Citations (0)
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

2015 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (179)
Blu-285, a Potent and Selective Inhibitor for Hematologic Malignancies with KIT Exon 17 Mutations

2015 Blood
Show All
- Source
- Cite
- Save
Citations (12)
O048 : First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway

2015 Journal of Hepatology
Show All
- Source
- Cite
- Save
Citations (1)
Discovery of N-(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), A Highly Selective, Orally Bioavailable Inhibitor of Aurora Kinases with Activity against Multidrug-Resistant Cancer Cell Lines

2015 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (30)
First Selective KIT D816V Inhibitor for Patients with Systemic Mastocytosis

2014 Blood
Show All
- Source
- Cite
- Save
Citations (12)